Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | MicrobiomeTrials← Back to trialsNCT04262856
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2020-05-28Est. Completion: 2025-07-09
Enrollment target: 151 participants Locations- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Innovative Clinical Research Institute (ICRI), Whittier, California, United States
- Florida Cancer Specialists, Englewood, Florida, United States
- Florida Cancer Specialists, Gainesville, Florida, United States
- Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
- Florida Cancer Specialists - East, West Palm Beach, Florida, United States
- Baptist Health Lexington, Lexington, Kentucky, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion, Ridgewood, New Jersey, United States
- Clinical Research Alliance, Lake Success, New York, United States
- Northwell Health Cancer Institute, Lake Success, New York, United States
- Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
- Allegheny General Hospital (AGH)-Alleghney Singer Research Institute, Pittsburgh, Pennsylvania, United States
Other microbiome trials you might be interested in
Non-small Cell Lung Cancer
This trial is a registrational Phase II/III, randomized, open-label, multicenter study to evaluate the efficacy and safe…
Shanghai, ChinaEst. completion Dec 2032
Recurrent Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Unresectable Lung Non-Small Cell Carcinoma
Sarah Cannon Research Institute, Nashville, Tennessee, United StatesThe Center For Cancer And Blood Disorders (Texas Cancer Care), Fort Worth, Texas, United StatesMillennium Oncology, Houston, Texas, United StatesOncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United StatesVirginia Cancer Specialists, Fairfax, Virginia, United StatesBorder Medical Oncology, Albury, AustraliaCoffs Harbour Health Campus, Coffs Harbour, AustraliaAdelaide Cancer Centre, Elizabeth Vale, AustraliaShoalhaven Cancer Care Centre, Nowra, AustraliaMcGill University Health Centre (MUHC) - The Montreal Children's Hospital (MCH), Montreal, CanadaHong Kong United Oncology Centre, Hong Kong, Hong KongQueen Elizabeth Hospital (Hong Kong), Hong Kong, Hong KongCurie Oncology, Singapore, SingaporeKosin University Gospel Hospital, Busan, South KoreaChungbuk National University Hospital (CBNUH), Cheongju-si, South KoreaChonnam University Hospital, Hwasun, South KoreaGachon University Gil Medical Center, Incheon, South KoreaChonbuk National University Hospital, Jeonju, South KoreaSeoul National University Bundang Hospital, Seongnam-si, South KoreaAsan Medical Center, Seoul, South KoreaKangbuk Samsung Hospital, Seoul, South KoreaKorea University Anam Hospital, Seoul, South KoreaSt Vincent Hospital of the Catholic University of Korea, Suwon, South KoreaCatholic University of Korea, Uijeongbu St. Mary's Hospital, Uijeongbu-si, South KoreaTaipei Medical University - Shuang Ho Hospital, New Taipei City, TaiwanChi Mei Hospital, Tainan, TaiwanNational Cheng Kung University Hospital, Tainan, TaiwanNational Taiwan University Hospital, Taipei, TaiwanTaipei Medical University Hospital, Taipei, TaiwanChang Gung Memorial Hospital at Linkou, Taoyuan, TaiwanThis phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) …
Anchorage, United StatesEst. completion Dec 31, 2028
Non Small Cell Lung Cancer
The purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non…
Birmingham, United StatesEst. completion Apr 27, 2027